In two recent double-blind clinical trials of fetal ventral mesencephalic cell transplants into the striatum in patients with Parkinson's disease (PD), a significant proportion of the grafted patients developed dyskinetic side effects, which were not seen in the sham operated patients. Comparison between dyskinetic and non-dyskinetic grafted patients in one of the trials suggested that an uneven pattern of striatal reinnervation might be the leading cause of the dyskinesias. Here, we studied the importance of graft placement for the development of dyskinesias in parkinsonian rats. Abnormal involuntary movements resembling peak-dose dyskinesias seen in PD patients were induced by daily injections of L-DOPA for 6 weeks. The dyskinetic animals received about 130.000 fetal ventral mesencephalic cells as single grafts placement in the rostral or the caudal aspect of the head of striatum. The results show that grafts placed in the caudal, but not the rostral, part are effective in reducing the L-DOPA-induced limb and orolingual dyskinesia, predominantly seen as hyperkinesia. The same grafts, however, also induced a new type of dyskinetic behavior after activation with amphetamine, which were not seen in non-grafted lesion controls. The severity of these abnormal involuntary movements was significantly correlated with a higher graft-derived dopaminergic reinnervation in the caudal aspect of the head of striatum relative to the rostral part. The results indicate that graft-induced dyskinesias in PD patients may be linked to single, small graft deposits that provide an uneven, patchy reinnervation of the putamen. D
Introduction
Current pharmacological treatment of Parkinson's disease (PD) is primarily based on oral administration of l-3,4-dihydroxyphenylalanine (l-DOPA), the precursor of dopamine (DA). However, high incidence of complications including, among others, induction of abnormal involuntary movements or postures, termed dyskinesias, is a major concern (Marsden et al., 1982; Quinn, 1998; Fahn, 2000) . Observations in PD patients, as well as data obtained from animal experiments, suggest that fluctuations in striatal DA concentration as a result of the pulsatile l-DOPA administration is one of the main contributors to the development of these side effects (Fahn, 2000; Jenner, 2000; Nutt et al., 2000; Carlsson et al., 2005) .
Transplantation of fetal DA neurons is currently being explored as a restorative treatment strategy for PD patients. As grafted DA neurons provide a new fiber terminal network in the striatum, patients suffering from l-DOPA-induced dyskinesias would be expected to improve after transplantation. In open-label clinical transplantation studies, reductions in dyskinesias (% time in ''on'' with dyskinesias) have been reported in some patients, while the remaining patients either did not benefit or had worsened (Defer et al., 1996; Hagell et al., 1999; Hauser et al., 1999; Brundin et al., 2000) . The reason for this variable response remains unclear. Two recent double-blind placebo-controlled trials (Freed et al., 2001; Olanow et al., 2003) investigating the usefulness of fetal DA neuron transplantation in PD patients have raised concerns that the grafts may induce a new type of dyskinesia (Hagell et al., 2002; Lindvall and Bjorklund, 2004; Winkler et al., 2005) . In the first study, 4 out of 33 grafted patients developed severe involuntary movements (Greene et al., 1999; Freed et al., 2001) , and in the second study, off-state dyskinesia was observed in 13 out of 23 grafted patients (Olanow et al., 2003) . These graft-induced dyskinesias (GIDs), which persisted after l-DOPA withdrawal, were generally mild, but were disabling and required surgery in 3 cases (Freed et al., 2004) . Further investigation of the patients from the first trial, using [ 18 F]-DOPA positron emission tomography (PET), showed that in the dyskinetic patients, there were asymmetric and localized increases in the PET signal in the ventral putamen, while this was not seen in the grafted non-dyskinetic patients (Ma et al., 2002) . This lead to the conclusion that focal, unbalanced increases in striatal DA function caused by a patchy DA innervation may contribute to the development of these GIDs. 
